New mRNA RSV vaccine shows promise in phase 3 trial for adults 50+
⭐️ VACCINE ⭐️
Completed
This study tested an experimental mRNA vaccine (mRNA-1345) to protect against RSV, a virus that can cause serious breathing problems in older adults. About 3,300 people aged 50 and older took part. The vaccine was given alone or at the same time as a flu shot or COVID-19 booster.…
Phase: PHASE3 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Apr 26, 2026 20:03 UTC